Cullgen is developing innovative targeted protein degradation (TPD) therapeutics. Their proprietary technology platform, uSMITE™, leverages the power of E3 ligases to allow them to create small molecules that selectively degrade disease-causing proteins. Cullgen's pipeline includes several promising drug candidates targeting various therapeutic areas, including oncology, inflammation, and neurodegeneration. Their research has the potential to revolutionize the treatment of these diseases by addressing previously undruggable targets.

Cullgen

Founded: 2018
Location: San Diego, California
Employee range: 1-50
Clinical stage: Clin1
Therapy area: Solid tumors
Drug types: ONC, PN
Lead product: CG001419
Funding: 100 - 500M

Drug notes:

About:

Jobs: